产品封面图

pdCas9-humanized

收藏
  • ¥1000
  • ZYbscience
  • 中国/美国
  • ZY44246
  • 2025年07月11日
    avatar
    上海泽叶生物科技有限公司
    11 年钻石会员

  • 企业认证

    点击 QQ 联系

    • 相关产品推荐更多 >

    万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件：

      -20℃低温保存

    • 保质期：

      三年

    • 英文名：

      pdCas9-humanized

    • 库存：

      20

    • 供应商：

      泽叶生物

    载体基本信息

    出品公司: ZYbscience
    载体名称: pdCas9-humanized
    质粒类型: CRISPR-Cas9载体；基因敲除载体；逆病毒载体
    高拷贝/低拷贝: 高拷贝
    插入位点: 限制性内切酶，多克隆位点
    启动子: MSCV
    载体大小: 10477bp
    5' 测序引物及序列: CCGGAATTAGATCTCGCCACCATGGAC
    3' 测序引物及序列: CCGGTAGAATTCTATACCTTTCTCTTCT
    载体标签: 3x NLS(C ter)
    载体抗性: 氨苄青霉素
    筛选标记: Puromycin
    克隆菌株: DH5alpha
    宿主细胞（系）: 常规哺乳动物细胞等
    备注: Mutation D10A H840A (catalytically inactive)；The dCas9 contains an N612K mutation that does not effect function.
    产品目录号: ZY44246
    稳定性: 稳表达
    组成型/诱导型: 组成型
    病毒/非病毒: 逆病毒

    载体质粒图谱和多克隆位点信息

    pdCas9-humanized载体图谱


    载体简介

    载体序列

    LOCUS       pdCas9-humanized	10477 bp 	DNA	SYN
DEFINITION  pdCas9-humanized
ACCESSION   
KEYWORDS    
SOURCE      
  ORGANISM  other sequences; artificial sequences; vectors.
FEATURES             Location/Qualifiers
     source          1..10477
                     /organism="pdCas9-humanized"
                     /mol_type="other DNA"
     misc_feature    654..1403
                     /label="psi_plus_pack"
     misc_feature    990..1397
                     /label="gag"
     misc_feature    1333..1355
                     /label="MSCV_primer"
     misc_feature    1333..1355
                     /label="pLXSN_5_primer"
     misc_feature    1371..1387
                     /label="pBABE_5_primer"
     CDS             1423..5610
                     /label="ORF frame 1"
                     /translation="MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK
                     KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLE
                     ESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH
                     MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSK
                     SRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD
                     NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL
                     LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK
                     LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY
                     YVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVL
                     PKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKE
                     DYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLT
                     LFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF
                     LKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQT
                     VKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKE
                     HPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKV
                     LTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKA
                     GFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQF
                     YKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIG
                     KATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS
                     MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV
                     AKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLF
                     ELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQH
                     KHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA
                     PAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDEGADPKKKRK
                     VDPKKKRKVDPKKKRKV*"
     CDS             complement(3043..3516)
                     /label="ORF frame 2"
                     /translation="MDKLHEVAISESVALKEIKNGLSALFVPDSVDEFAAKASPSGIS
                     SPFKLLHHFIVEQMGVGLKPLLDHFPVLEQSESQDNVLKDVLVLLIVQKILVLDDLKQ
                     IMVGTQACVEPIFDPANLHRVEAFNFLEIVLLQLLHGHLSIGLEQKVHNCLLLFA*"
     misc_feature    5539..5559
                     /label="SV40 NLS"
                     /translation="MDKLHEVAISESVALKEIKNGLSALFVPDSVDEFAAKASPSGIS
                     SPFKLLHHFIVEQMGVGLKPLLDHFPVLEQSESQDNVLKDVLVLLIVQKILVLDDLKQ
                     IMVGTQACVEPIFDPANLHRVEAFNFLEIVLLQLLHGHLSIGLEQKVHNCLLLFA*"
     misc_feature    5545..5559
                     /label="NLS"
                     /translation="MDKLHEVAISESVALKEIKNGLSALFVPDSVDEFAAKASPSGIS
                     SPFKLLHHFIVEQMGVGLKPLLDHFPVLEQSESQDNVLKDVLVLLIVQKILVLDDLKQ
                     IMVGTQACVEPIFDPANLHRVEAFNFLEIVLLQLLHGHLSIGLEQKVHNCLLLFA*"
     misc_feature    complement(5655..5678)
                     /label="MSCV_rev_primer"
                     /translation="MDKLHEVAISESVALKEIKNGLSALFVPDSVDEFAAKASPSGIS
                     SPFKLLHHFIVEQMGVGLKPLLDHFPVLEQSESQDNVLKDVLVLLIVQKILVLDDLKQ
                     IMVGTQACVEPIFDPANLHRVEAFNFLEIVLLQLLHGHLSIGLEQKVHNCLLLFA*"
     CDS             5900..6739
                     /label="ORF frame 2"
                     /translation="MEAGRPLGQRPIAALLLRFLGSEAGKGWVRGRAQGRAQGRGGRP
                     KVLRRPGILHASKAHVCRAVLLFLISGPFDLQPKLTMTEYKPTVRLATRDDVPRAVRT
                     LAAAFADYPATRHTVDPDRHIERVTELQELFLTRVGLDIGKVWVADDGAAVAVWTTPE
                     SVEAGAVFAEIGPRMAELSGSRLAAQQQMEGLLAPHRPKEPAWFLATVGVSPDHQGKG
                     LGSAVVLPGVEAAERAGVPAFLETSAPRNLPFYERLGFTVTADVEVPEGPRTWCMTRK
                     PGA*"
     misc_feature    6052..6071
                     /label="mPGK_F_primer"
                     /translation="MEAGRPLGQRPIAALLLRFLGSEAGKGWVRGRAQGRAQGRGGRP
                     KVLRRPGILHASKAHVCRAVLLFLISGPFDLQPKLTMTEYKPTVRLATRDDVPRAVRT
                     LAAAFADYPATRHTVDPDRHIERVTELQELFLTRVGLDIGKVWVADDGAAVAVWTTPE
                     SVEAGAVFAEIGPRMAELSGSRLAAQQQMEGLLAPHRPKEPAWFLATVGVSPDHQGKG
                     LGSAVVLPGVEAAERAGVPAFLETSAPRNLPFYERLGFTVTADVEVPEGPRTWCMTRK
                     PGA*"
     CDS             complement(6065..6790)
                     /label="ORF frame 1"
                     /translation="MGSCAPFGRALRVVGRASGTGLAGHAPGARSFGHLDVGGDGEAE
                     PLVEGEVAGRGGLQEGGHPGALGRLHSGEHDGAAQTLALVVGRDADGGQEPRGLLGPV
                     RRQEAFHLLLRGQPGTAQLGHARADLGEHRPRFDALRRGPDRHRGAVVRDPHLADVEP
                     DAREEEFLQLGDPLDVAVRIDGVARGGVVGERGGEGAYGPGDVVAGGEAHRGLVLGHG
                     KLGLQVERPGDEEEENSAADVRF*"
     gene            6140..6739
                     /label="puro (variant)"
                     /gene="puro (variant)"
                     /translation="MGSCAPFGRALRVVGRASGTGLAGHAPGARSFGHLDVGGDGEAE
                     PLVEGEVAGRGGLQEGGHPGALGRLHSGEHDGAAQTLALVVGRDADGGQEPRGLLGPV
                     RRQEAFHLLLRGQPGTAQLGHARADLGEHRPRFDALRRGPDRHRGAVVRDPHLADVEP
                     DAREEEFLQLGDPLDVAVRIDGVARGGVVGERGGEGAYGPGDVVAGGEAHRGLVLGHG
                     KLGLQVERPGDEEEENSAADVRF*"
     promoter        complement(7518..7536)
                     /label="M13_reverse_primer"
                     /translation="MGSCAPFGRALRVVGRASGTGLAGHAPGARSFGHLDVGGDGEAE
                     PLVEGEVAGRGGLQEGGHPGALGRLHSGEHDGAAQTLALVVGRDADGGQEPRGLLGPV
                     RRQEAFHLLLRGQPGTAQLGHARADLGEHRPRFDALRRGPDRHRGAVVRDPHLADVEP
                     DAREEEFLQLGDPLDVAVRIDGVARGGVVGERGGEGAYGPGDVVAGGEAHRGLVLGHG
                     KLGLQVERPGDEEEENSAADVRF*"
     misc_feature    complement(7535..7557)
                     /label="M13_pUC_rev_primer"
                     /translation="MGSCAPFGRALRVVGRASGTGLAGHAPGARSFGHLDVGGDGEAE
                     PLVEGEVAGRGGLQEGGHPGALGRLHSGEHDGAAQTLALVVGRDADGGQEPRGLLGPV
                     RRQEAFHLLLRGQPGTAQLGHARADLGEHRPRFDALRRGPDRHRGAVVRDPHLADVEP
                     DAREEEFLQLGDPLDVAVRIDGVARGGVVGERGGEGAYGPGDVVAGGEAHRGLVLGHG
                     KLGLQVERPGDEEEENSAADVRF*"
     promoter        complement(7571..7600)
                     /label="lac_promoter"
                     /translation="MGSCAPFGRALRVVGRASGTGLAGHAPGARSFGHLDVGGDGEAE
                     PLVEGEVAGRGGLQEGGHPGALGRLHSGEHDGAAQTLALVVGRDADGGQEPRGLLGPV
                     RRQEAFHLLLRGQPGTAQLGHARADLGEHRPRFDALRRGPDRHRGAVVRDPHLADVEP
                     DAREEEFLQLGDPLDVAVRIDGVARGGVVGERGGEGAYGPGDVVAGGEAHRGLVLGHG
                     KLGLQVERPGDEEEENSAADVRF*"
     gene            complement(8683..9543)
                     /label="Ampicillin"
                     /gene="Ampicillin"
                     /translation="MGSCAPFGRALRVVGRASGTGLAGHAPGARSFGHLDVGGDGEAE
                     PLVEGEVAGRGGLQEGGHPGALGRLHSGEHDGAAQTLALVVGRDADGGQEPRGLLGPV
                     RRQEAFHLLLRGQPGTAQLGHARADLGEHRPRFDALRRGPDRHRGAVVRDPHLADVEP
                     DAREEEFLQLGDPLDVAVRIDGVARGGVVGERGGEGAYGPGDVVAGGEAHRGLVLGHG
                     KLGLQVERPGDEEEENSAADVRF*"
     CDS             complement(8683..9543)
                     /label="ORF frame 2"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
                     IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
                     YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
                     DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
                     LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
                     EIGASLIKHW*"
     promoter        complement(9585..9613)

    风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验

    • Bioengineered Skin Humanized Model of Psoriasis

      This protocol describes the generation of a skin humanized mouse model for psoriasis using bioengineering approaches. This method is relatively simple, highly reproducible and ensures the obtention of a large and homogenous number

    • Production of Human or Humanized Antibodies in Mice

      such conventional strategies combined with mice that are either genetically engineered to carry humanized immunoglobulin (Ig) genes or engrafted with a human immune system, it is thus easy to obtain and immortalize clones that produce either fully human Ig

    • Humanized Model to Study Leukemic Stem Cells

      The xenotransplantation model has been instrumental for the identification and characterization of human leukemic stem cells. In this chapter we will discuss the development of the immunodeficient model in the understanding of leukemogenesis

    查看更多相关实验 >
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    载体pdCas9-humanized
    ¥800
    上海沪震实业有限公司
    2025年07月13日询价
    pLVX-Puro载体
    ￥750
    上海盖宁生物科技有限公司
    2025年12月29日询价
    lentiCRISPR v2载体
    ¥1000
    上海泽叶生物科技有限公司
    2025年07月16日询价
    HEK-293T-ACE2过表达细胞株(HEK-293T- ACE2 Cell Line)
    ￥18500
    翌圣生物科技（上海）股份有限公司
    2025年10月15日询价
    pGADT7载体
    ¥1000
    上海信裕生物科技有限公司
    2025年07月16日询价
    pdCas9-humanized
    ¥1000